In conclusion, it seems that UDCA, OCA and even Nor-UDCA will remain as main therapies for PBC and PSC, but the addition of FXR agonist and PPAR agonist may improve the management of liver cirrhosis. Here, NR1H4 is linked to primary biliary cholangitis.